Browsing by Author Kesaniemi, Y. Antero

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 6 of 6
Issue DateTitleAuthor(s)Citation
2007Abstract 3691: Features Of Metabolic Syndrome Identify Individuals With Type 2 Diabetes Mellitus At High Risk For Cardiovascular Events And Greater Absolute Benefits Of FenofibrateBarter, Philip; Copt, Samuel; Keech, Anthony (Tony); Pardy, Christopher; Best, James; D'Emden, Michael C.; Drury, P; Ehnholm, Christian; FIELD study investigators, Fenofibrate Intervention and Event Lowering in Diabetes; Kesaniemi, Y. Antero; Scott, Russell; Taskinen, M.; Tse, Dana; Central Clinical School: Heart Research Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreAbstract 3691: Features Of Metabolic Syndrome Identify Individuals With Type 2 Diabetes Mellitus At High Risk For Cardiovascular Events And Greater Absolute Benefits Of Fenofibrate, Circulation (Baltimore), vol.116, N/A,pp II_838-N/A
2012Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) studyForder, Peta; Keech, Anthony (Tony); Simes, Robert John; Voysey, Merryn; Glasziou, Paul; Hamer, Andrew; Hunt, David; Kesaniemi, Y. Antero; Mahar, Leo; Mann, Stewart; Tonkin, Andrew; Waites, Jonathon H; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreEffects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, American Heart Journal, vol.163, 3, 2012,pp 508-514
2010Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) StudyDonoghoe, Mark; Gebski, Val; Keech, Anthony (Tony); O'Connell, Rachel; Simes, Robert John; Ting, R; Best, J; Davis, T. M. E.; Drury, P.L.; Glasziou, Paul .P.; Jenkins, Alicia J.; Kesaniemi, Y. Antero; Scott, R; Sullivan, D; Whiting, M. J.; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreEffects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study, Diabetologia: clinical and experimental diabetes and metabolism, vol.54, 2,pp 280-290
2005Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.Barter, Philip; Best, James; Davis, Tracey; Forder, Peta; Glasziou, Paul; Keech, Anthony (Tony); Pillai, Avineshwaran; Scott, R; Simes, Robert John; Sullivan, David; Taskinen, M; Drury, P; et, al; Kesaniemi, Y. Antero; Central Clinical School: Medicine; Medicine Faculty Office; Western Clinical School: Medicine (Westmead); School of Public Health: NH&MRC Clinical Trials Centre; Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Central Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Molecular Bioscience; Central Clinical School: MedicineEffects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial., The Lancet, vol.366,(9500),2005,pp 1849-1861
2010Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.Burgess, David; Keech, Anthony (Tony); Li, Li Ping; Sy, Raymond; Williamson, E; Zannino, Diana; Zhang, Jun; Davis, Timothy; Hunt, David; Kesaniemi, Y. Antero; Laakso, Markku; Lehto, Seppo; Mann, S; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Concord Clinical School: Psychological Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; AnaesthesiaIncidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study., European Heart Journal (English Edition), vol.31, 1,pp 92-99
2005Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia.Barter, Philip; Bersot, Thomas; et, al; Kesaniemi, Y. Antero; Mahley, Robert W.; McPherson, Ruth; Waeber, Gerard; Waterworth, Dawn M.; Wilton, Steven D.; Wyszynski, Diego F.; Yu, Yi; Central Clinical School: MedicineMultiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia., Journal of Lipid Research, vol.46,(10),2005,pp 2202-2213